Preparation for US launch of IRRAflow®
ongoing, CE mark catheter re-certification now expected at YE
2018
STOCKHOLM, Nov. 8, 2018 /PRNewswire/ -- Third quarter,
July–September 2018
- Net revenue totaled SEK 0.0
million (11.3).
- Operating loss (EBIT) amounted to SEK
-40.0 million (-7.2).
- Loss after tax totaled SEK -41.8
million (-7.3).
- Earnings per share before and after dilution amounted to
SEK -1.75 (-0.42).
Full year to date January–September 2018
- Net revenue totaled SEK 6.0
million (11.3).
- Operating loss (EBIT) amounted to SEK
-93.2 million (-37.8).
- Loss after tax totaled SEK -88.8
million (-37.7).
- Earnings per share before and after dilution amounted to
SEK -3.74 (-2.19).
Important events during the third quarter
FDA clearance of IRRAflow
IRRAS received 510(k) clearance from the US Food and Drug
Administration (FDA) for the company's IRRAflow system and
consumable products. The FDA decision means that the company now
has the right to market and sell IRRAflow in the US.
Preparations for US launch are ongoing and include contacts with
key neurosurgery centers in the US and numerous marketing
activities that are planned through the end of the year.
Preparation launch in the US
IRRAS has started the sales preparations in the US and recruited
four regional managers with significant experience bringing medical
devices to large markets.
Important events after the end of the third quarter
New Board member
At an extraordinary general meeting on October 1, Eva Nilsagård was elected as a new
Board member. Eva Nilsagård has a long and broad experience in
finance and business development of listed companies.
Update on re-certification of catheter CE mark
LNE/G-MED, the company's certification body expects that the
re-certification process of the IRRAflow catheter to be
completed by the end of the year.
Expanded management team
As of October 19, IRRAS's
executive management group consists of Kleanthis Xanthopoulos, Fredrik Alpsten,
Will Martin, Lance Bolling and Kellie
Fontes. The expanded management group also includes
Adam Sampson, Dino De Cicco, Dessi
Lyakov and Sabina Berlin.
Comments from the President and
CEO
During the third quarter of 2018, IRRAS obtained its most
significant milestone as a company to date – we were pleased to
receive the FDA clearance for our innovative IRRAflow
device, which we believe will become the new standard for safe,
efficient, and controlled drainage of intracranial fluids.
The United States is our most
important market and we are hopeful to begin recording sales
revenues in the US at year-end 2018.
To ensure we have a successful launch in the US, we have, during
the third quarter, significantly enhanced our sales and commercial
teams in the US with highly qualified individuals who have advanced
numerous medical devices to large markets.
At the beginning of October, we participated, for the first time
with an approved product, at the Congress of Neurological Surgeons
(CNS) in Houston, Texas. The
initial feedback on our product from physicians in the US has been
very positive and we look forward to working within these networks
to grow recognition and future use of IRRAflow.
While preparing for launch in the US, we also focused
substantial efforts on the EU market during the third quarter. The
catheter CE mark re-certification has been delayed due to notified
body's backlog and we now expect to receive the certificate by the
end of the year and anticipate that sales can be resumed in EU in
the beginning of 2019.
Third quarter financial overview
Due to the delay in the re-certification of the CE mark in the
EU and pending launch in the US, no sales were reported during the
third quarter of 2018.
EBIT for the third quarter of the year was SEK -40.0 million (-7.2). The increased costs are
primarily attributable to the planned organizational expansion. The
average number of employees in the third quarter of 2018 was 21,
compared with 8 in the year-earlier period. The preparations for a
launch in the US later this year also contributed to the increased
costs. In addition, operating expenses in this period include
one-time extra costs of SEK 11
million. The one-time costs mainly refer to extra costs in
2018 due to the delayed CE-mark of the catheter and remaining costs
for the two product recalls in 2017.
Our available liquidity as of September
30, 2018 is SEK 190 million,
including short- and long-term financial investments.
Building for future growth at IRRAS
At IRRAS, our mission is clear: to change the lives of millions
by creating medical products that transform the current treatment
of intracranial bleedings. We believe that IRRAflow will
ultimately become the new standard of care in this field and we
continue to make progress toward accomplishing this mission.
With the recent FDA clearance in the US and the anticipated
re-certification of the CE mark in the EU, as well as registration
of our product in additional countries, we believe the future of
IRRAS is bright.
President and CEO Kleanthis G.
Xanthopoulos, Ph.D.
The full interim report is enclosed.
This document is considered information that IRRAS is obliged to
disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact person above, on November 8,
2018 at 8:00 a.m. (CET).
Investor and Media Contact:
Fredrik Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-ab--publ--interim-report-january-september-2018,c2666923
The following files are available for download:
http://mb.cision.com/Main/16550/2666923/941087.pdf
|
IRRAS AB (Publ)
INTERIM FINANCIAL REPORT JANUARY â€" SEPTEMBER 2018
(PDF)
|